Aromatase inhibitor
-
Antihormonal treatment for hormone receptor (HR) positive breast cancer has highly beneficial effects on both recurrence rates and survival. We investigate adherence and persistence in this group of patients.
12p vileonardodavinci 23-12-2023 8 2 Download
-
The adjuvant treatment with Aromatase Inhibitor (AI) is considered standard of care for postmenopausal breast cancer (BC) women with hormone receptor-positive (HR+), however, it often causes adverse effects such as cancer-related fatigue (CRF).
20p vialfrednobel 23-12-2023 4 3 Download
-
Aromatase inhibitors (AI) are frequently used to treat hormone-receptor-positive breast cancer, but they have multiple adverse effects (e.g., osteoporosis, arthralgia), resulting in premature therapy discontinuation/ switch. Physical activity (PA) can attenuate these negative effects and improve quality of life (QoL).
17p vioracle 29-09-2023 5 2 Download
-
Bài viết trình bày đánh giá chất lượng cuộc sống và tình trạng đau khớp trên bệnh nhân ung thư vú điều trị Aromatase inhibitor tại Trung tâm Ung Bướu Thái Nguyên. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả tiến hành trên 109 người bệnh ung thư vú điều trị aromatase inhibitor tại Trung tâm Ung Bướu Thái Nguyên từ 1/2018 đến 05/2022.
9p vifred 23-12-2022 20 6 Download
-
A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer.
12p vikolindagrabar 27-07-2022 5 2 Download
-
Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, and pharmacokinetics of entinostat monotherapy and combined entinostat/exemestane in Japanese patients.
12p vimahuateng 26-11-2021 11 1 Download
-
Bài viết trình bày đánh giá chất lượng cuộc sống và tình trạng đau khớp trên bệnh nhân ung thư vú điều trị aromatase inhibitor tại Trung tâm Ung Bướu Thái Nguyên. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả tiến hành trên 109 người bệnh ung thư vú điều trị aromatase inhibitor tại Trung tâm Ung Bướu Thái Nguyên từ 1/2018 đến 6/2020.
8p vijenchae2711 24-07-2021 26 1 Download
-
Early sex differentiation genes of zebrafish remain an unsolved mystery due to the difficulty to distinguish the sex of juvenile zebrafish. However, aromatase inhibitors (AIs) could direct juvenile zebrafish sex differentiation to male and even induce ovary-to-testis reversal in adult zebrafish.
10p vijeeni2711 24-07-2021 9 0 Download
-
Quantification of vertebral bone marrow (VBM) water–fat composition has been proposed as advanced imaging biomarker for osteoporosis. Estrogen deficiency is the primary reason for trabecular bone loss in postmenopausal women. By reducing estrogen levels aromatase inhibitors (AI) as part of breast cancer therapy promote bone loss.
7p vivermont2711 28-01-2021 10 2 Download
-
Despite positive results from large phase III clinical trials proved that it is possible to prevent estrogen-responsive breast cancers with selective estrogen receptor modulators and aromatase inhibitors, no significant results have been reached so far to prevent hormone non-responsive tumors.
10p vijisoo2711 30-09-2020 6 1 Download
-
Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs.
7p vijennie2711 29-09-2020 10 1 Download
-
It is known that suboptimal adherence rates may affect endocrine treatments for breast cancer, but little information has been reported whether any efforts to improve treatment adherence have been successful.
9p vijennie2711 29-09-2020 16 1 Download
-
The role of estrogen receptor beta (ER-β) in breast cancer (BC) remains unclear. Some studies have suggested that ER-β may oppose the actions of estrogen receptor alpha (ER-α), and clinical evidence has indicated that the loss of ER-β expression is associated with a poor prognosis and resistance to endocrine therapy.
12p vijennie2711 29-09-2020 25 1 Download
-
After the failure of a non-steroidal aromatase inhibitor (nsAI) for postmenopausal patients with metastatic breast cancer (mBC), it is unclear which of various kinds of endocrine therapy is the most appropriate. A randomized controlled trial was performed to compare the efficacy and safety of daily toremifene 120 mg (TOR120), a selective estrogen receptor modulator, and exemestane 25 mg (EXE), a steroidal aromatase inhibitor.
9p vijennie2711 29-09-2020 10 1 Download
-
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL).
11p virose2711 25-09-2020 9 1 Download
-
We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer.
7p virose2711 25-09-2020 11 0 Download
-
Neoadjuvant endocrine therapy with an aromatase inhibitor has shown efficacy comparable to that of neoadjuvant chemotherapy in patients with postmenopausal breast cancer. Preclinical and clinical studies have shown that the antidiabetic drug metformin has anti-tumor activity.
5p virose2711 25-09-2020 18 1 Download
-
Despite the excellent results obtained with hormone therapy, the long treatment period and the side effects associated with its use make patient adherence difficult. Moreover, certain aspects of health care can mitigate or exacerbate non-adherence.
8p virose2711 24-09-2020 27 1 Download
-
Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that use of cyclooxygenase (COX) inhibitors is associated with reduced breast cancer risk.
13p virose2711 22-09-2020 9 2 Download
-
Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are histologically similar to Ductal Breast Cancer. We report what we believe to be the first case in literature of metastatic salivary duct carcinoma (SDC) of the parotid gland with objective response to tamoxifen and aromatase inhibitors, achieving a long-term stability of disease with no associated toxicity.
4p vilisa271 22-09-2020 16 1 Download